Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

CLYM116

Other · developed by Climb Bio

Phase 1 Most advanced trial

CLYM Developer

1 Registered trials

What is CLYM116?

CLYM116 is an agent administered by subcutaneous injection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Developer: Climb Bio, Inc. (CLYM)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07248865	Phase 1	Healthy Volunteers	Recruiting	CLYM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Volunteers

More from Climb Bio

Budoprutug Phase 1/2

Sources

ClinicalTrials.gov NCT07248865

Updated Oct 11, 2026. Something wrong or missing? Report it on the CLYM page.

Follow CLYM, the company behind CLYM116

See CLYM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CLYM catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z